AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

4SC AG

Report Publication Announcement Nov 4, 2015

5_rns_2015-11-04_3b906917-a9da-4e8c-a912-484e169ccdb7.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

News Details

Corporate | 4 November 2015 15:00

Announcement: 4SC AG to host conference call on 11 November 2015 to present third quarter results of 2015

DGAP-News: 4SC AG / Key word(s): Conference/Miscellaneous

2015-11-04 / 15:00


Announcement

4SC AG to host conference call on 11 November 2015 to present third quarter results of 2015

Planegg-Martinsried, Germany, 4 November 2015 – 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs especially for cancer, will announce third quarter results 2015 of the 4SC Group and publish the Company’s report on the first nine months of 2015 on 11 November 2015. On this day the Management Board of 4SC AG will host a conference call at 3pm CET (9am EST) to inform about the consolidated financial statements and important developments in the reporting period and beyond.

Investors, financial analysts, and journalists participating in the conference call can access via the following telephone numbers:

Date: 11 November 2015

Time: 3pm CET (9am EST)

Dial-in numbers:

+49(0)89 1214 00699 (Germany)

+44(0)20 3427 1909 (UK)

+1646 254 3362 (USA)

+49(0)89 1214 00699 (other countries)

Conference-ID: 8804549

After the conference call a replay will be available in the section “Investors” / “Events & Presentations” / “Conference Calls & Webcasts” of the website www.4sc.com .

Ends

About 4SC

4SC is a biotechnology company dedicated to the research and development of small-molecule drugs for treating diseases with high unmet medical needs focusing on cancer. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company’s pipeline comprises promising products that are in various stages of clinical development. 4SC’s aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 69 employees (60 FTEs) at 30 September 2015. 4SC AG is listed on the Prime Standard of the Frankfurt Stock Exchange (ISIN DE000A14KL72).

Cautionary statement regarding forward-looking statements

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.

For more information please visit www.4sc.com or contact:

4SC AG

Jochen Orlowski, Corporate Communications & Investor Relations

jochen.orlowski(at)4sc.com, Tel.: +49-89-7007-6366

MC Services

Katja Arnold, Michelle Kremer

katja.arnold(at)mc-services.eu, Tel.: +49-89-2102-2840

The Trout Group

Chad Rubin

crubin(at)troutgroup.com, Tel.: +1-646-378-2947


2015-11-04 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Media archive at www.dgap-medientreff.de and www.dgap.de


Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: [email protected]
Internet: www.4sc.de
ISIN: DE000A14KL72
WKN: A14KL7
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
- - -
407413  2015-11-04 show this

Talk to a Data Expert

Have a question? We'll get back to you promptly.